Acadian Asset Management LLC Zymeworks Inc. Transaction History

Acadian Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$29.21 - $46.58 $2.19 Million - $3.49 Million	-74,849 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$33.67 - $40.0 $1.95 Million - $2.32 Million	-57,876 Reduced 43.61%	74,849 $2.7 Million
Q1 2020 May 11, 2020	BUY	$24.28 - $49.8 $3.22 Million - $6.61 Million	132,725 New	132,725 $4.71 Million
Q3 2019 Nov 07, 2019	SELL	$22.78 - $29.08 $5.32 Million - $6.79 Million	-233,472 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$15.0 - $22.49 $1.04 Million - $1.56 Million	69,337 Added 42.24%	233,472 $5.14 Million
Q1 2019 May 09, 2019	BUY	$14.02 - $16.74 $711,318 - $849,320	50,736 Added 44.74%	164,135 $2.65 Million
Q4 2018 Feb 07, 2019	BUY	$10.95 - $15.44 $322,674 - $454,985	29,468 Added 35.11%	113,399 $1.67 Million
Q3 2018 Oct 30, 2018	BUY	$12.21 - $16.61 $1.02 Million - $1.39 Million	83,931 New	83,931 $1.32 Million
Q2 2018 Jul 24, 2018	SELL	$11.13 - $21.86 $20,534 - $40,331	-1,845 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$7.93 - $13.41 $14,630 - $24,741	1,845 New	1,845 $23,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $856M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.